Kazuhito Kawata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4783004/publications.pdf

Version: 2024-02-01

47	824	471371	552653
papers	citations	17	26
		h-index	g-index

52	52	52	847
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clinical Gastroenterology and Hepatology, 2023, 21, 370-379.	2.4	30
2	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp>?â€”Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
3	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter caseâ€control study. Journal of Gastroenterology, 2022, 57, 19-29.	2.3	8
4	Timeâ€course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatology Research, 2022, 52, 235-246.	1.8	7
5	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
6	Neutrophilâ€lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 698-706.	0.8	27
7	Macâ€2â€binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. Hepatology Communications, 2022, 6, 1855-1869.	2.0	3
8	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria â€“ Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
9	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, 2022, 11, 3796-3808.	1.3	21
10	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Scientific Reports, 2022, 12, 8421.	1.6	4
11	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34
12	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 857-864.	0.8	3
13	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	1.4	28
14	The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Hepatology Research, 2021, 51, 80-89.	1.8	7
15	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterology Report, 2021, 9, 133-138.	0.6	21
16	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. Oncology, 2021, 99, 518-527.	0.9	5
17	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. Liver Cancer, 2021, 10, 115-125.	4.2	12
18	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	1.9	45

#	Article	IF	Citations
19	Giant Hepatomegaly with Spleno-testicular Enlargement in a Patient with Apolipoprotein A-I Amyloidosis: An Uncommon Type of Amyloidosis in Japan. Internal Medicine, 2021, 60, 575-581.	0.3	3
20	Ursodeoxycholic acid impairs liverâ€infiltrating Tâ€cell chemotaxis through IFNâ€Î³ and CX3CL1 production in primary biliary cholangitis. European Journal of Immunology, 2021, 51, 1519-1530.	1.6	10
21	Dilated main pancreatic duct can be a negative predictor of pancreatitis related to biliary SEMS insertion across the papilla. Scandinavian Journal of Gastroenterology, 2021, 56, 865-869.	0.6	4
22	Therapeutic efficacy of lenvatinib as thirdâ€line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	1.8	15
23	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	1.9	18
24	Impact of modified albuminâ€“bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474.	1.6	13
25	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Scientific Reports, 2021, 11, 16663.	1.6	30
26	Spontaneous clearance of serum hepatitis C virus RNA in an untreated patient with decompensated cirrhosis. Acta Hepatologica Japonica, 2021, 62, 555-560.	0.0	0
27	Plateletâ€“lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. European Journal of Gastroenterology and Hepatology, 2021, 32, 261-268.	0.8	9
28	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. International Journal of Molecular Sciences, 2020, 21, 4939.	1.8	8
29	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infectious Diseases and Therapy, 2020, 9, 851-866.	1.8	16
30	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Oncology, 2020, 98, 295-302.	0.9	24
31	Neutrophilâ€toâ€lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver International, 2020, 40, 968-976.	1.9	51
32	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver International, 2020, 40, 1926-1933.	1.9	14
33	Bezafibrate Improves GLOBE and UKâ€PBC Scores and Longâ€Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology, 2019, 70, 2035-2046.	3.6	83
34	Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. Clinical Journal of Gastroenterology, 2018, 11, 302-308.	0.4	2
35	A case of a primary hepatic so-called adenosarcoma with heterotopic ossification: possibly of biliary adenofibroma origin. Human Pathology, 2018, 73, 108-113.	1.1	5
36	Clinical characteristics and risk factors for stentâ€“stone complex formation following biliary plastic stent placement in patients with common bile duct stones. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 448-454.	1.4	12

#	Article	IF	Citations
37	Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. Gut and Liver, 2018, 12, 201-207.	1.4	22
38	Critical role of CREBHâ€mediated induction of transforming growth factor Î²2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells. Hepatology, 2017, 66, 1430-1443.	3.6	23
39	Factors Related to the Beneficial Effects of Tolvaptan Treatment for Hepatic Ascites. Japanese Journal of Clinical Pharmacology and Therapeutics, 2016, 47, 17-20.	0.1	0
40	Chorea induced by simeprevir and PEG-IFN and rivabirin therapy for chronic hepatitis C. Acta Hepatologica Japonica, 2015, 56, 103-108.	0.0	1
41	Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2015, 35, 956-962.	0.5	3
42	Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. ISRN Hepatology, 2014, 2014, 1-7.	0.9	3
43	Mesenchymal hamartoma of the liver: Report of a case and review of the literature. Acta Hepatologica Japonica, 2014, 55, 756-763.	0.0	0
44	Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis. PLoS ONE, 2013, 8, e74225.	1.1	49
45	The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical Reviews in Allergy and Immunology, 2012, 43, 230-241.	2.9	28
46	Hemorrhagic radiation gastritis successfully treated with repeated intra-arterial steroid infusions. Clinical Journal of Gastroenterology, 2011, 4, 34-38.	0.4	2
47	Enhanced Hepatic Nrf2 Activation After Ursodeoxycholic Acid Treatment in Patients with Primary Biliary Cirrhosis. Antioxidants and Redox Signaling, 2010, 13, 259-268.	2.5	48